INVIKAFUSP ALFA
UNII 2E6V84F6FT

Substance Identification & Data

This profile provides standardized clinical and technical data for Invikafusp Alfa, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 2E6V84F6FT.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2894138-60-2 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

2E6V84F6FT

CAS Registry Number

2894138-60-2

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

INVIKAFUSP ALFA

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C206925

National Cancer Institute reference terminology for clinical and research data.

Substance Type

Invikafusp Alfa

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Invikafusp Alfa. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Invikafusp Alfa

Common Names & Synonyms

Immunoglobulin G1 [351-cysteine,368-serine,370-alanine,409-valine,de-448-glycine,de-C-terminal lysine], anti-(human T cell receptor germline-encoded variable chain Vβ6/β10) (human-Mus musculus monoclonal BKM0259 γ1-chain), disulfide with human-Mus musculus monoclonal BKM0259 κ-chain, (228→149),(231→152),(351→277)-tris(disulfide) with human interleukin 2 fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin G1 [127-alanine,184-cysteine, 196-tryptophan,de-276-glycine,de-C-terminal lysine] (human γ1-chain C region C-terminal fragment)

gamma 1 heavy chain (1-447) [VH (Homo sapiens IGHV1-3*01 -(IGHD) -IGHJ4*01, CDR-Kabat [5.17.10] (31-35.50-66.99-108)) (1-119) -Homo sapiens IGHG1*03 (CH1 (120-217), hinge (218-232), CH2 N299>A (233-342), CH3 Y351>C, T368>S, L370>A, Y409>V (343-447), CHS G448>del, K449>del) (120-447)], (222-214')-disulfide with kappa light chain (1'-214')[V-KAPPA (Homo sapiens IGKV1-9*01 -IGKJ2*01, CDR-Kabat [11.7.9](24'-34'.50'-56'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (108'-214')]; (228-149'':231:152'': 351:277'')-trisdisulfide with human interleukin 2 (IL-2, T-cell growth factor) (C125>A)-variant (1-133) fused via (G4S) 2 peptide linker (134-143) to a Fc fragment of human immunoglobulin G1 (144-368) [Homo sapiens IGHG1*03, hinge N-terminal EPKSC deleted (144-153), CH2 N220>A (154-263), CH3 S277>C, T289>W (264-368), CHS G369>del, K370>del] (produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1 cells, glycoform alfa)

humanized immunoglobulin G1-kappa anti-(human T cell receptor germline-encoded variable chain Vβ6/β10) monomer disulfide bridged to human interleukin 2 (IL-2, T-cell growth factor) ((C125>A)-variant fused via (G4S)2 peptide linker to immunoglobulin G1 Fc fragment, glycoform alfa

invikafusp alfa [INN]

External Clinical & Regulatory Resources

Previous UNII2E6CN8IAJ4

Next UNII2E76572CUD